Current Pharmaceutical Biotechnology aims to cover all the latest and outstanding developments in Pharmaceutical Biotechnology. Each issue of the journal includes timely in-depth/mini reviews, original research articles and letters written by leaders in the field, covering a range of current topics in scientific areas of Pharmaceutical Biotechnology. Invited and unsolicited review articles are welcome. The journal encourages contributions describing research at the interface of drug discovery and pharmacological applications, involving in vitro investigations and pre-clinical or clinical studies. Scientific areas within the scope of the journal include pharmaceutical chemistry, biochemistry and genetics, molecular and cellular biology, and polymer and materials sciences as they relate to pharmaceutical science and biotechnology. In addition, the journal also considers comprehensive studies and research advances pertaining food chemistry with pharmaceutical implication.
Areas of interest include:
DNA/protein engineering and processing
Omics (genomics, proteomics, metabolomics and systems biology)
Industrial bioprocesses for drug production and development
Special Issues devoted to crucial topics, providing the latest comprehensive information on cutting-edge areas of research and technological advances, are welcome.
Current Pharmaceutical Biotechnology is an essential journal for academic, clinical, government and pharmaceutical scientists who wish to be kept informed and up-to-date with the latest and most important developments.
Davide Prosperi Department of Biotechnology and Bioscience University of Milano-Bicocca Milano Italy
Prof. Davide Prosperi is Associate Professor in Biochemistry at the University of Milano Bicocca (Unimib), Department of Biotechnology and Bioscience. Head of the NanoBioLab of Unimib, he is devoted to biomedical and biophysical applications of nanotechnology. In particular, the research activity of Davide Prosperi involves the design, synthesis, functionalization and characterization of colloidal, polymeric and biomimetic nanoparticles for biomedical applications, with particular focus on the diagnosis and treatment of cancer and inflammatory diseases. He is author of over 100 scientific publications. He is one of the author of the patent “Nanoconstructs with pharmacological activity” (n° WO2014013473-A1), and co-founder of the spin-off company inTHEna srl, aiming to design and development of molecules, nanostructures and technologies for biomedical studies and diagnosis, prevention and therapy of human and animal diseases.